{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T23:28:32Z","timestamp":1790724512580,"version":"4.1.0"},"reference-count":20,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2018,1,1]],"date-time":"2018-01-01T00:00:00Z","timestamp":1514764800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2018,1]]},"DOI":"10.1016\/j.ijantimicag.2017.06.022","type":"journal-article","created":{"date-parts":[[2017,7,11]],"date-time":"2017-07-11T01:46:21Z","timestamp":1499737581000},"page":"62-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":103,"title":["In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii"],"prefix":"10.1016","volume":"51","author":[{"given":"Harald","family":"Seifert","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danuta","family":"Stefanik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joyce A.","family":"Sutcliffe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul G.","family":"Higgins","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0010","doi-asserted-by":"crossref","first-page":"538","DOI":"10.1128\/CMR.00058-07","article-title":"Acinetobacter baumannii: emergence of a successful pathogen","volume":"21","author":"Peleg","year":"2008","journal-title":"Clin Microbiol Rev"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0015","doi-asserted-by":"crossref","first-page":"826","DOI":"10.1111\/j.1469-0691.2006.01456.x","article-title":"Carbapenem resistance in Acinetobacter baumannii: mechanisms and epidemiology","volume":"12","author":"Poirel","year":"2006","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0020","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1093\/jac\/dkp428","article-title":"Global spread of carbapenem-resistant Acinetobacter baumannii","volume":"65","author":"Higgins","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0025","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1128\/AAC.01388-10","article-title":"Efflux-mediated antibiotic resistance in Acinetobacter spp","volume":"55","author":"Coyne","year":"2011","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0030","doi-asserted-by":"crossref","first-page":"3921","DOI":"10.1128\/AAC.02927-15","article-title":"Colistin and polymyxin B dosage regimens against Acinetobacter baumannii: differences in activity and the emergence of resistance","volume":"60","author":"Cheah","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0035","doi-asserted-by":"crossref","first-page":"567","DOI":"10.1007\/s40265-016-0545-8","article-title":"Review of eravacycline, a novel fluorocycline antibacterial agent","volume":"76","author":"Zhanel","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0040","doi-asserted-by":"crossref","first-page":"3840","DOI":"10.1128\/AAC.00436-16","article-title":"In vitro activity of eravacycline against carbapenem-resistant Enterobacteriaceae and Acinetobacter baumannii","volume":"60","author":"Livermore","year":"2016","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0045","doi-asserted-by":"crossref","first-page":"1802","DOI":"10.1128\/AAC.04809-14","article-title":"Activity of eravacycline against Enterobacteriaceae and Acinetobacter baumannii, including multidrug-resistant isolates, from New York City","volume":"59","author":"Abdallah","year":"2015","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0050","series-title":"M07-A10. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard\u2014tenth edition","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2015"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0055","series-title":"Performance standards for antimicrobial susceptibility testing","author":"Clinical and Laboratory Standards Institute (CLSI)","year":"2016"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0060","doi-asserted-by":"crossref","first-page":"351","DOI":"10.1016\/j.ijantimicag.2006.01.004","article-title":"Multiplex PCR for genes encoding prevalent OXA carbapenemases in Acinetobacter spp","volume":"27","author":"Woodford","year":"2006","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0065","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0153014","article-title":"Head-to-head comparison of two multi-locus sequence typing (MLST) schemes for characterization of Acinetobacter baumannii outbreak and sporadic isolates","volume":"11","author":"Tomaschek","year":"2016","journal-title":"PLoS ONE"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0070","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1093\/cid\/civ225","article-title":"Fatal outbreak of an emerging clone of extensively drug-resistant Acinetobacter baumannii with enhanced virulence","volume":"61","author":"Jones","year":"2015","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0075","doi-asserted-by":"crossref","first-page":"860","DOI":"10.1017\/ice.2015.52","article-title":"High endemic rates of OXA-23-producing carbapenem-resistant Acinetobacter baumannii isolates caused by the persistence of major clones in hospitals in a Brazilian city 5 years after an outbreak","volume":"36","author":"Pagano","year":"2015","journal-title":"Infect Control Hosp Epidemiol"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0080","doi-asserted-by":"crossref","first-page":"2057","DOI":"10.1007\/s00134-015-4079-4","article-title":"Task force on management and prevention of Acinetobacter baumannii infections in the ICU","volume":"41","author":"Garnacho-Montero","year":"2015","journal-title":"Intensive Care Med"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0085","doi-asserted-by":"crossref","first-page":"e009956","DOI":"10.1136\/bmjopen-2015-009956","article-title":"Multicentre open-label randomised controlled trial to compare colistin alone with colistin plus meropenem for the treatment of severe infections caused by carbapenem-resistant Gram-negative infections (AIDA): a study protocol","volume":"6","author":"Dickstein","year":"2016","journal-title":"BMJ Open"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0090","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1016\/j.ijantimicag.2014.12.033","article-title":"In vitro activity of ceftazidime, ceftaroline and aztreonam alone and in combination with avibactam against European Gram-negative and Gram-positive clinical isolates","volume":"45","author":"Testa","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0095","doi-asserted-by":"crossref","first-page":"1589","DOI":"10.1093\/jac\/dkq218","article-title":"AdeABC-mediated efflux and tigecycline MICs for epidemic clones of Acinetobacter baumannii","volume":"65","author":"Hornsey","year":"2010","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0100","doi-asserted-by":"crossref","first-page":"224","DOI":"10.1001\/jamasurg.2016.4237","article-title":"Assessing the efficacy and safety of eravacycline vs ertapenem in complicated intra-abdominal infections in the investigating Gram-negative infections treated with eravacycline (IGNITE 1) trial: a randomized clinical trial","volume":"152","author":"Solomkin","year":"2017","journal-title":"JAMA Surg"},{"key":"10.1016\/j.ijantimicag.2017.06.022_bib0105","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1128\/AAC.02036-13","article-title":"Phase I, open-label, safety and pharmacokinetic study to assess bronchopulmonary disposition of intravenous eravacycline in healthy men and women","volume":"58","author":"Connors","year":"2014","journal-title":"Antimicrob Agents Chemother"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302716?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857917302716?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2022,11,17]],"date-time":"2022-11-17T19:31:37Z","timestamp":1668713497000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857917302716"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,1]]},"references-count":20,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2018,1]]}},"alternative-id":["S0924857917302716"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.022","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2018,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"In-vitro activity of the novel fluorocycline eravacycline against carbapenem non-susceptible Acinetobacter baumannii","name":"articletitle","label":"Article Title"},{"value":"International Journal of Antimicrobial Agents","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2017.06.022","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2017 Elsevier B.V. and International Society of Chemotherapy. All rights reserved.","name":"copyright","label":"Copyright"}]}}